Effects of DNA methyltransferase inhibitors (DNMTIs) on MDS-derived cell lines

Experimental Hematology

Volumn 41, Issue 2, 2013, Pages 189-197

  Tsujioka, Takayuki ^a   Yokoi, Akira ^b   Uesugi, Mai ^b   Kishimoto, Mitsuyo ^c   Tochigi, Aki ^a   Suemori, Sinichiro ^a   Tohyama, Yumi ^d   Tohyama, Kaoru ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b EISAI CO LTD   (Japan)

^c Kawasaki College of Allied Health Professions   (Japan)

^d HIMEJI DOKKYO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CHEMOKINE RECEPTOR CXCR4; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; TRANSCRIPTION FACTOR GATA 1;

ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL GROWTH; CONCENTRATION RESPONSE; CONTROLLED STUDY; CXCR4 GENE; DNA DAMAGE; DNA DETERMINATION; DNA METHYLATION; DRUG CYTOTOXICITY; DRUG SENSITIVITY; ENZYME INHIBITION; GATA 1 GENE; GENE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LONG INTERSPERSED REPEAT; MYELODYSPLASTIC SYNDROME; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AZACITIDINE; CELL CYCLE; CELL DIVISION; CELL LINE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA DAMAGE; DNA METHYLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GENE EXPRESSION PROFILING; HL-60 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; MYELODYSPLASTIC SYNDROMES;

EID: 84873517691     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2012.10.006     Document Type: Article

References (50)

1. Bennett J.M., Catovsky D., Daniel M.T., et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982, 51:189-199.
2. Brunning R.D., Orazi A., Germing U., et al. Myelodysplastic Syndrome/ Neoplasms, Overview: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008, 87-107. IARC, Lyon, France. 6th ed. S.H. Swerdlow, E. Campo, N.L. Harris (Eds.).
3. Cazzola M., Malcovati L. Myelodysplastic syndromes-coping with ineffective hematopoiesis. N Engl J Med 2005, 352:536-538.
4. Issa J.P., Kantarjian H.M. Targeting DNA methylation. Clin Cancer Res 2009, 15:3938-3946.
5. Quintás-Cardama A., Santos F.P., Garcia-Manero G. Therapy with azanucleosides for myelodysplastic syndromes. Nat Rev Clin Oncol 2010, 7:433-444.
6. Silverman L.R., Demakos E.P., Peterson B.L., et al. Randomized controlled trial of azacitidine in patients with the myeloblastic syndrome: a study of the cancer and Leukemia Group B. J Clin Oncol 2002, 20:2429-2440.
7. Kornblith A.B., Herndon J.E., Silverman L.R., et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase B trial: a Cancer and Leukemia Group B study. J Clin Oncol 2002, 20:2441-2452.
8. Kantarjian H., Issa J.P., Rosenfield C.S., et al. Decitabine improve patient outcomes in myelodysplastic syndromes: results of a phase B randomized study. Cancer 2006, 106:1794-1803.
9. WijerMans P, Suciu S, Baila L, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate or high risk MDS not eligible for intensive chemotherapy: final results of the randomized phase B study (06011) of the EORTC Leukemia and German MDS study groups. Blood (ASH Annual Meeting Abstracts). 2008;112:226.
10. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., et al. International Vidaza High-Risk MDS Survival Study Group Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10:223-232.
11. Ravandi F., Issa J.P., Garcia-Manero G., et al. Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. Cancer 2009, 115:5746-5751.
12. Lübbert M., Bertz H., Rüter B., et al. Non-intensive treatment with low-dose 5-aza-2'-deoxycitidine (DAC) prior to allogenic blood SCT of older MDS/ AML patients. Bone Marrow Transplant 2009, 44:585-588.
13. Shen L., Kantarjian H., Guo Y., et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 2010, 28:605-613.
14. Stresemann C., Bokelmann I., Mahlknecht U., Lyko F. Azacytidine causes complex DNA methylation responses in myeloid leukemia. Mol Cancer Ther 2008, 7:2998-3005.
15. Lavelle D., DeSimone J., Hankewych M., Kousnetzova T., Chen Y.H. Decitabine induces cell cycle arrest at the G1 phase via p21(WAF1) and the G2/M phase via the p38 MAP kinase pathway. Leuk Res 2003, 27:999-1007.
16. Valdez B.C., Li Y., Murray D., Corn P., Champlin R.E., Andersson B.S. 5-Aza-2'-deoxycytidine sensitizes busulfan-resistant myeloid leukemia cells by regulating expression of genes involved in cell cycle checkpoint and apoptosis. Leuk Res 2010, 34:364-372.
17. Flotho C., Claus R., Batz C., et al. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia 2009, 23:1019-1028.
18. Hollenbach P.W., Nguyen A.N., Brady H., et al. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS One 2010, 5:e9001.
19. Tohyama K., Tsutani H., Ueda T., Nakamura T., Yoshida Y. Establishment and characterization of a novel myeloid cell line from the bone marrow of a patient with the myelodysplastic syndrome. Br J Haematol 1994, 87:235-242.
20. Tohyama K., Tohyama Y., Nakayama T., Ueda T., Nakamura T., Yoshida Y. A novel factor-dependent human myelodysplastic cell line, MDS92, contains haemopoietic cells of several lineages. Br J Haematol 1995, 91:795-799.
21. Drexler H.G., Dirks W.G., Macleod R.A. Many are called MDS cell lines: one is chosen. Leuk Res 2009, 33:1011-1016.
22. Matsuoka A., Tochigi A., Kishimoto M., et al. Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis. Leukemia 2010, 24:748-755.
23. Ormerod M.G., Collins M.K.L., Rodriguez-Tarduchy G., Robertson D. Apoptosis in Interleukin-3 dependent haemopoietic cells: quantification by two flow cytometric methods. J Immunol Meth 1992, 153:57-65.
24. Vermes I., Haanen C., Steffens-Nakken H., Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein-labeled Annexin V. J Immunol Meth 1995, 184:39-51.
25. Höglund A., Nilsson L.M., Forshell L.P., Maclean K.H., Nilsson J.A. Myc sensitizes p53-deficient cancer cells to the DNA-damaging effects of the DNA methyltransferase inhibitor decitabine. Blood 2009, 113:4281-4288.
26. Holmfeldt P., Brannstrom K., Stenmark S., Gullberg M. Deciphering the cellular functions of the Op18/Stathmin family of microtubule-regulators by plasma membrane-targeted localization. Mol Biol Cell 2003, 14:3716-3729.
27. Shi Y., Tohyama Y., Kadono T., He J., et al. Protein tyrosine kinase Syk is required for pathogen engulfment in complement-mediated phagocytosis. Blood 2006, 107:4554-4562.
28. Tsujioka T, Matsuoka A, Tohyama Y, Tohyama K: Approach to a new therapeutics: Investigation by the use of MDS-derived cell lines. Curr Pharm Design. In press.
29. Qin T., Youssef E.M., Jelinek J., et al. Effect of cytarabine and decitabine in combination in human leukemic cell lines. Clin Cancer Res 2007, 13:4225-4232.
30. Qin T., Jelinek J., Si J., Shu J., Issa J.P. Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines. Blood 2009, 113:659-667.
31. Qin T., Castoro R., El Ahdab S., et al. Mechanisms of resistance to decitabine in the myelodysplastic syndrome. PLoS One 2011, 6:e23372.
32. Estécio M.R., Yan P.S., Ibrahim A.E., et al. High-throughput methylation profiling by MCA coupled to CpG island microarray. Genome Res 2007, 17:1529-1536.
33. Kroep J.R., Loves W.J., van der Wilt C.L., et al. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol Cancer Ther 2002, 1:371-376.
34. Flasshove M., Strumberg D., Ayscue L., et al. Structural analysis of the deoxycytidine kinase gene in patients with acute myeloid leukemia and resistance to cytosine arabinoside. Leukemia 1994, 8:780-785.
35. Murphy K.M., Ranganathan V., Farnsworth M.L., Kavallaris M., Lock R.B. Bcl2 inhibits Bax translocation from cytosol to mitochondria during drug-induced apoptosis of human tumor cells. Cell Death Differ 2000, 7:102-111.
36. Adams J.M., Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998, 281:1322-1326.
37. Minn A.J., Kettlun C.S., Liang H., et al. Bcl2 regulates apoptosis by heterodimerization-dependent and -independent mechanisms. EMBO J 1999, 18:632-643.
38. Yu J., Zhang L., Hwang P.M., Kinzler K.W., Volgelstein B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 2001, 7:673-682.
39. Neveraux Q.L., Reed J.C. IAP family proteins-suppressors of apoptosis. Genes Dev 1999, 13:239-252.
40. Kimura S., Kuramoto K., Homan J., et al. Antiproliferative and antitumor effects of azacitidine against the human myelodysplastic syndrome cell line SKM-1. Anticancer Res 2012, 32:795-798.
41. Li E. Chromatin modification and epigenetic reprogramming in mammalian development. Nat Rev Genet 2002, 3:662-673.
42. Claus R., Lübbert M. Epigenetic targets in hematopoietic malignancies. Oncogene 2003, 22:6489-6496.
43. Leone G., D'Alo F., Zardo G., Voso M.T., Nervi C. Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemia. Curr Med Chem 2008, 15:1274-1287.
44. Patel K., Dickson J., Macleod K., Jodrell D., Ramsahoye B. Targeting of 5-aza-2'-deoxycitidine residues by chromatin-associated DNMT1 induces proteasomal degradation of the free enzyme. Nucleic Acids Res 2010, 38:4313-4324.
45. Jiemjit A., Fandy T.E., Carraway H., et al. P21 (Waf1/CIP1) induction by 5-azacytosine nucleosides DNA damage. Oncogene 2008, 27:3615-3623.
46. Palii S.S., Van Emburgh B.O., Sankpal U.T., Brown K.D., Robertson K.D. DNA methylation inhibitor 5-aza-20-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferase 1 and 3B. Mol Cell Biol 2008, 28:752-771.
47. Karpf A.R., Moore B.C., Ririe T.O., Jones D.A. Activation of the p53 DNA damage response pathway after inhibition of DNA methyltransferase by 5-aza-2'-deoxycytidine. Mol Pharmacol 2001, 59:751-757.
48. Ruiz-Magana M.J., Rodoríguez-Valgas J.M., Morales J.C., Saldivia M.A., Schulze-Osthoff K., Ruiz-Ruiz C. The DNA methyltransferase inhibitors zebularine and decitabine induce mitochondria-mediated apoptosis and DNA damage in p53 mutant leukemic T cells. Int J Cancer 2012, 30:1195-1207.
49. Schmelz K., Wagner M., Doken B., Tamm I. 5-Aza-20-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia. Int J Cancer 2005, 114:683-695.
50. Fabiani E., Leone G., Giachelia M., et al. Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia. Leuk Lymphoma 2010, 51:2275-2284.